Heart attack drug may fix 'Hidden' vessel damage
NCT ID NCT06787430
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug nicorandil can improve blood flow in the heart's tiny vessels after a heart attack. About 170 patients having emergency angioplasty will receive either nicorandil or a placebo directly into their heart artery. The goal is to see if nicorandil reduces microvascular dysfunction, a common problem that can lead to worse outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nicorandil
- What this could lead to
- If it works, this could point toward a simple, cheap way to improve blood flow in the heart's tiny vessels after a heart attack, potentially reducing long-term damage.
- What could go wrong
- This is a relatively small, early-phase trial testing a short-term drug effect. The benefit may be small or not translate to better long-term outcomes, and the drug can cause low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEMI - ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.